文献速递重症综合管理与镇静镇痛心脑血管急症

颅脑创伤后的输血需求:一项随机可行性对照试验

Transfusion requirements after head trauma: a randomized feasibility controlled trial.
PubMed 文献 · Crit Care · 2019-03-12
一句话结论中重度颅脑创伤患者中,限制性输血策略(血红蛋白阈值7 g/dL)组住院死亡率高于宽松策略(9 g/dL)组,宽松组6个月神经功能有更优趋势。

该研究纳入ICU收治的中重度颅脑创伤成人患者44例,随机分为限制性输血策略组(血红蛋白阈值7 g/dL,23例)与宽松策略组(阈值9 g/dL,21例),策略持续至14天或ICU出院。主要终点为两组血红蛋白平均差异,14天内限制性组平均血红蛋白8.4±1.0 g/dL低于宽松组9.3±1.3 g/dL(p<0.01),限制性组红细胞输注单位更少(35 vs 66,p=0.02)。宽松组创伤后血管痉挛发生率显著更低(4/21,3% vs 15/23,65%;p<0.01),限制性组住院死亡率更高(7/23 vs 1/21;p=0.048),宽松组6个月神经功能有更优趋势(p=0.06)。作者结论为试验达到可行性标准。

要点

  • 中重度颅脑创伤ICU患者中,限制性输血组(阈值7 g/dL)住院死亡率7/23高于宽松组(阈值9 g/dL)1/21(p=0.048)。
  • 宽松输血策略组创伤后血管痉挛发生率4/21(3%)显著低于限制性组15/23(65%)(p<0.01)。
  • 14天内平均血红蛋白限制性组8.4±1.0 g/dL低于宽松组9.3±1.3 g/dL(p<0.01),限制性组红细胞输注单位更少(35 vs 66,p=0.02)。
  • 血红蛋白浓度与大脑中动脉血流速度呈负相关(r=-0.265,p<0.01),经颅多普勒超声评估。
  • 宽松组6个月神经功能状态有更优趋势(p=0.06),试验达到可行性标准。

适用人群与场景

  • 连续纳入的入住ICU的成年中重度颅脑创伤患者,全部符合条件者纳入随机分组。

诊断标准与关键阈值

  • 限制性输血策略:血红蛋白输血阈值为7 g/dL。
  • 宽松输血策略:血红蛋白输血阈值为9 g/dL。
  • 输血策略持续至14天或ICU出院。

处置流程与药物剂量

  • 限制性策略组按血红蛋白阈值7 g/dL触发红细胞输注,宽松策略组按9 g/dL触发,策略持续至14天或ICU出院。

红旗征与不能漏的情况

  • 创伤后血管痉挛:宽松策略组发生率4/21(3%)显著低于限制性组15/23(65%)(p<0.01)。

研究设计与关键结果

  • 随机可行性对照试验,共44例,宽松组21例、限制性组23例,两组基线无差异。
  • 主要终点:14天内平均血红蛋白限制性组8.4±1.0 g/dL vs 宽松组9.3±1.3 g/dL(p<0.01)。
  • 红细胞输注单位:限制性组35 vs 宽松组66(p=0.02)。
  • 血红蛋白与大脑中动脉血流速度负相关(r=-0.265,p<0.01),经颅多普勒超声评估。
  • 创伤后血管痉挛发生率:宽松组4/21(3%)vs 限制性组15/23(65%)(p<0.01)。
  • 住院死亡率:限制性组7/23 vs 宽松组1/21(p=0.048)。
  • 6个月神经功能状态:宽松组有更优趋势(p=0.06)。

证据类型、等级与局限

  • 随机可行性对照试验;试验注册号ClinicalTrials.gov NCT02203292,注册日期2014年7月29日。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论为试验达到可行性标准;限制性组血红蛋白更低、红细胞输注更少;住院死亡率更低及6个月神经功能更优倾向于宽松组。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Anemia is frequent among patients with traumatic brain injury (TBI) and is associated with an increased risk of poor outcome. The optimal hemoglobin concentration to trigger red blood cell (RBC) transfusion in patients with TBI is not clearly defined.

METHODS: All eligible consecutive adult patients admitted to the intensive care unit (ICU) with moderate or severe TBI were randomized to a "restrictive" (hemoglobin transfusion threshold of 7 g/dL), or a "liberal" (threshold 9 g/dL) transfusion strategy. The transfusion strategy was continued for up to 14 days or until ICU discharge. The primary outcome was the mean difference in hemoglobin between groups. Secondary outcomes included transfusion requirements, intracranial pressure management, cerebral hemodynamics, length of stay, mortality and 6-month neurological outcome.

RESULTS: A total of 44 patients were randomized, 21 patients to the liberal group and 23 to the restrictive group. There were no baseline differences between the groups. The mean hemoglobin concentrations during the 14-day period were 8.4 ± 1.0 and 9.3 ± 1.3 (p < 0.01) in the restrictive and liberal groups, respectively. Fewer RBC units were administered in the restrictive than in the liberal group (35 vs. 66, p = 0.02). There was negative correlation (r = - 0.265, p < 0.01) between hemoglobin concentration and middle cerebral artery flow velocity as evaluated by transcranial Doppler ultrasound and the incidence of post-traumatic vasospasm was significantly lower in the liberal strategy group (4/21, 3% vs. 15/23, 65%; p < 0.01). Hospital mortality was higher in the restrictive than in the liberal group (7/23 vs. 1/21; p = 0.048) and the liberal group tended to have a better neurological status at 6 months (p = 0.06).

CONCLUSIONS: The trial reached feasibility criteria. The restrictive group had lower hemoglobin concentrations and received fewer RBC transfusions. Hospital mortality was lower and neurological status at 6 months favored the liberal group.

TRIAL REGISTRATION: ClinicalTrials.gov, NCT02203292 . Registered on 29 July 2014.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Gobatto ALN, Link MA, Solla DJ, et al. Transfusion requirements after head trauma: a randomized feasibility controlled trial. Crit Care. 2019. PMID: 30871608. doi:10.1186/s13054-018-2273-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。